This is the latest episode of the free DDW narrated podcast, titled “Where are the global breakthroughs, opportunities and developments in cancer research?”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Global breakthroughs in cancer drug discovery”, “… Read More
This is the latest episode of the free DDW narrated podcast, “Important therapies for the future of immunotherapy”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Improving quality control for CAR T cell therapies”, and… Read More
Listen to this article on the DDW Podcast: DDW’s Megan Thomas spoke with Frédéric Triebel, the French immunologist/oncologist who is best known for his 1990 discovery of the LAG-3 immune control mechanism. Triebel shares insights from his career, expands on his experience with the company he… Read More
Immutep revealed positive final data from Part C of the TACTI-002 Phase II trial at the ASCO 2023 Annual Meeting in Chicago, US. The trial evaluated eftilagimod alpha (efti), a soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with MSD’s (Merck) anti-PD-1 therapy Keytruda… Read More
Listen to this article on the DDW Podcast: Immutep is working to understand and develop therapeutics that relate to Lymphocyte Activation gene-3 or ‘LAG-3’ which is a cell surface molecule that plays a vital role in regulating the immune system. LAG-3 was discovered by Frederic Triebel, CSO,… Read More
DDW Deputy Editor Reece Armstrong speaks to Professor Frederic Triebel, CSO of Immutep about the approval of Bristol Myers Squibb’s LAG-3 antibody and why it’s causing so much excitement in the sector. Recently, the Food and Drug Administration (FDA) approved the first combination therapy… Read More
